art8k2008-3rdqtrearnings.htm
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): November 14,
2008
Arrhythmia
Research Technology, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
(State
or other jurisdiction of Incorporation
or
organization)
|
1-9731
(Commission
File Number)
|
72-0925679
(I.R.S.
Employer Identification Number)
|
25 Sawyer
Passway
Fitchburg,
MA 01420
(Address
of principal executive offices and zip code)
(978)
345-5000
(Registrant's
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
2.02 Results
of Operations and Financial Condition.
On
November 14, 2008, Arrhythmia Research Technology, Inc. (the "Company")
announced its financial results for the three and nine months ended September
30, 2008. The full text of the press release issued in connection
with the announcement is furnished as Exhibit 99.01 to this Current Report on
Form 8-K.
The
information in this Form 8-K and Exhibit 99.01 attached hereto shall not be
deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934
(the "Exchange Act") or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Fitchburg, Commonwealth of Massachusetts, on the
18th day of November, 2008.
|
|
ARRHYTHMIA
RESEARCH TECHNOLOGY, INC.
|
|
|
By: /s/ David A.
Garrison
|
|
|
Executive
Vice President and
|
Exhibit
Index